Drug Trial Radar · NCT07424690
Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
282
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Dec 15, 2031
Study completion Sep 15, 2034
Sponsor
- Lead sponsor
- Karolinska University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Hospital, Linkoeping; Sahlgrenska University Hospital; University Hospital, Umeå; Dept of Cardiology, Örebro University Hospital, Sweden; Lund University Hospital; Onassis Cardiac Surgery Centre; Uppsala University Hospital; Royal Adelaide Hospital
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure. The study compares two established treatment strategies: 1. Catheter ablation (an invasive procedure aimed at reducing AF by electrically isolating triggers in the heart, primarily through pulmonary vein isolation), and 2. Optimized medical therapy without AF ablation (medications for rate and/or rhythm control; AV node ablation with pacemaker may be used if clinically indicated according to routine care). Participants are randomized 1:1 to one of these strategies. All participants will receive an implantable loop recorder (a small heart rhythm monitor placed under the skin) to continuously track heart rhythm and measure AF burden over time. The study has two primary endpoints, tested with Holm-Bonferroni multiplicity control assessed over 24 months: 1. a composite of major clinical events (all-cause mortality, stroke, major bleeding, cardiac arrest, or hospitalization due to heart failure), and 2. patient-reported health-related quality of life (HRQoL), measured by the RAND-36 "General Health" domain. ACE-AF will provide evidence to guide treatment decisions for very elderly patients with symptomatic AF and help identify which patients benefit most from an ablation-based strategy compared with optimized medical therapy.
Conditions
- Atrial Fibrillation (AF)
- Atrial Fibrillation Ablation
- Elderly
Interventions
Catheter Ablation for Atrial FibrillationProcedure
Catheter ablation for symptomatic atrial fibrillation with pulmonary vein isolation (PVI) prioritized as the primary lesion set. Energy source and tools are selected according to local practice and operator discretion (no restriction to a specific technology), performed under routine standards of care at experienced centres.
Optimized Medical Therapy for Atrial FibrillationDrug
Guideline-directed rate and/or rhythm control tailored to the participant's clinical condition, including rate-control medications and/or antiarrhythmic drugs and cardioversion when clinically appropriate. AF ablation is not performed as part of this strategy.
Implantable Loop Recorder (ILR)Device
Subcutaneous implantable loop recorder used for continuous rhythm monitoring and quantification of atrial fibrillation burden throughout follow-up. Implanted in all participants according to protocol-defined workflow.
AV Node Ablation With Pacemaker implantationProcedure
AV node ablation with permanent pacing may be performed when clinically indicated according to routine care, as part of the optimized medical therapy strategy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite clinical endpoint (all-cause mortality, stroke, serious bleeding, cardiac arrest, or heart failure hospitalization)Time frame: 24 months after intervention (visit 2)
- Change in RAND-36 General Health scoreTime frame: Baseline to 24 months after intervention (visit 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Linköping University Hospital
Linköping, Sweden · Not yet recruiting
Karolinska University Hospital
Stockholm, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.